Dr Leslie Citrome on Coverage of Metabolic-Friendly Antipsychotics

Leslie Citrome, MD, MPH, of New York Medical College, discusses payer coverage of atypical antipsychotics with fewer metabolic side effects.

Transcript

What is the landscape like for patients trying to get coverage for atypical antipsychotis that cause fewer metabolic side effects?

We do have choices in terms of the array of antipsychotics that are available for the treatment of schizophrenia. Some may be more metabolically friendly than others. But they tend to be branded products, and so more costly. But it's not usually an impossibility to get them for our patients. I don't see huge obstacles in prescribing branded, atypical antipsychotics where they would be needed.